Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
New ticker. IRulya Therapeutics now trades under the ticker IRLA.
$230.4MCash on Hand
52.1mo Cash Runway
Follow QNCX by emailGet an email when QNCX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about QNCX, unsubscribe in one click. Privacy
📣 What QNCX Says Is Next
fourth quarter of 2026 · “The Company plans to initiate a Phase 2 study in SAPH in the fourth quarter of 2026, with data anticipated in the fourth quarter of 2028.”
Company press release, Nov 13, 2026 · SEC filing
first quarter of 2028 · “A Phase 2b trial ( NCT05798923 ) in PH-ILD is ongoing, and data is anticipated in the first quarter of 2028.”
Company press release, Nov 13, 2026 · SEC filing
fourth quarter of 2026 · LAM-001: “Sarcoidosis Associated Pulmonary Hypertension (SAPH): The Company plans to initiate a Phase 2 study of LAM-001 in SAPH in the fourth quarter of 2026, with data anticipated in the fourth quarter of 2028.”
Company press release, Nov 13, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 13, 2026 ·
Earnings Reported Q3 2026 net loss of $27.7 million, or $2.31 per share, versus $13.4 million a year earlier, with cash, cash equivalents and investments of $105.2 million as of September 30, 2026, expected to fund operations through the end of 2028. Name changed to IRulya Therapeutics, trading as IRLA on Nasdaq. Form 8-K · SEC filing · Press release
Oct 6, 2026 ·
Shareholder vote Stockholders approved a 2026 Equity Incentive Plan with an initial reserve of 821,872 shares and a 2026 ESPP with a reserve of 142,045 shares. They also approved raising authorized common stock from 250,000,000 to 275,000,000 shares, effective October 6, 2026. Form 8-K · SEC filing
Oct 2, 2026 ·
Leadership Three directors, June Bray, David Lamond and Christopher Senner, conditionally resigned effective two business days after a October 6, 2026 special meeting, contingent on stockholder approval of three proposals. Four new directors were conditionally appointed effective at that time. Form 8-K · SEC filing
Sep 4, 2026 ·
Listing Nasdaq notified Quince that stockholders' equity of ($35,324,000) as of June 30, 2026 falls short of the $10,000,000 minimum. The stock continues trading as QNCX. A compliance plan is due October 15, 2026, and the company proposes renaming to IRulya Therapeutics pending shareholder approval. Form 8-K · SEC filing
Aug 27, 2026 ·
Leadership President Charles Ryan's last day of employment will be September 8, 2026, with severance benefits under his Executive Change in Control and Severance Agreement dated September 1, 2023, as described in the proxy statement filed August 25, 2026. Form 8-K · SEC filing
Aug 25, 2026 ·
Shareholder vote Quince is holding a special stockholder meeting on October 6, 2026 to vote on issuing shares tied to the Orphai acquisition and a $115 million private placement, plus a charter change to raise authorized common stock from 250,000,000 to 275,000,000 shares, new equity plans, and a possible adjournment. Form DEF 14A · SEC filing
Aug 17, 2026 ·
Shareholder vote Quince plans a special stockholder meeting to approve issuing common stock on conversion of Series C Preferred and warrant exercises, which exceeds 20% of outstanding shares and may cause a change of control. Filed pro forma data shows $115,981 thousand cash as of June 30, 2026. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Mar 2028 · Phase 2 · Recruiting · LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) Registry primary completion date, not a results date
Dec 2028 · Phase 2 · Upcoming Trial · LAM-001 for the Treatment of Sarcoidosis Associated Pulmonary Hypertension (SAPH) Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not QNCX's own candidates): Atezolizumab, Rituximab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
QNCX holds $230.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $13.3M/quarter from operations,
an estimated runway of 52.1 months at that rate (BioRadar estimate, not company guidance).
Share count 10,841,470 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full QNCX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for QNCX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.